Study shows semaglutide extends lifespan in aging mice, suggests anti-aging potential

A recent study has found that administering semaglutide, a medication commonly sold as Wegovy or Ozempic, significantly extends the lifespan of older mice. The research, published in Scientific American, indicates that the drug, originally designed for weight loss and diabetes treatment, may also have anti-aging properties.

Semaglutide works by mimicking a hormone that regulates appetite and blood sugar levels. Over the years, scientists have been exploring its effects beyond weight management, particularly its potential to improve metabolic health and longevity. The urgency of this research is underscored by an aging global population, with the World Health Organization projecting that by 2050, nearly 2 billion people will be over the age of 60. Finding effective ways to enhance longevity and quality of life for older adults has become a pressing public health priority.

In the study, the researchers treated old mice with semaglutide and observed a remarkable increase in their lifespan compared to untreated mice. This finding adds to a growing body of evidence suggesting that regulating metabolism can influence aging processes. The researchers noted that the drug not only extended life but also improved overall health markers in the mice, such as reduced inflammation and better physical function. This raises hopes that similar benefits could be seen in humans, though further studies are needed.

Looking ahead, researchers are eager to explore the mechanisms behind semaglutide's effects on aging. Clinical trials will be necessary to determine if the drug can safely and effectively extend human lifespan. If successful, this could lead to new treatments that not only combat obesity and diabetes but also foster healthier aging. The implications for public health are substantial, potentially reducing the burden of age-related diseases and enhancing the quality of life for millions.